Condition: Sickle Cell Disease · Hematopoetic Stem Cell Transplant · Haploidentical Hematopoietic Stem Cell Transplant · Sponsor: Arkansas Children's Hospital Research Institute
This trial will determine whether adding ruxolitinib to a reduced intensity conditioning (RIC) regimen reduces the rate of graft failure following haploidentical (haplo) hematopoietic cell transplant (HCT) for children and young adults with sickle cell disease (SCD). This study will enroll and treat up to 24 participants. Recruitment is expected to last for about 2 years and participants will be followed for an additional 2 years post-HCT.
This description comes directly from the study's public registry record.
Laura McLaughlin, MD · 501-364-3908 · LMcLaughlin@uams.edu
Kayla Ortiz · 720-777-4151 · Kayla.Ortiz@childrenscolorado.org
Always discuss trial participation with your own doctor first.
| Children's Hospital of Colorado | Aurora, Colorado, United States | Not Yet Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Manning Family Children's | New Orleans, Louisiana, United States | Not Yet Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07252050